FindMyRecallSubscribe
Class I: serious health riskTerminated

Shire Human Genetic Therapies Natpara Recall

Natpara (parathyroid hormone) for Injection, 75 mcg, 2 pack medication cartridges, Rx o…

Shire Human Genetic Therapies, Inc. · Lexington, MA

Risk level
Class I
Reported by FDA
Oct 2, 2019
Recall ID
D-0037-2020
Check your lot numberHow we source this data

Summary

Shire Human Genetic Therapies recalled Natpara starting Sep 12, 2019. The FDA classified it as Class I (serious health risk) and published enforcement report D-0037-2020 on Oct 2, 2019. Reason: Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing. Status: Terminated.

Why it was recalled

Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing

Product description

Natpara (parathyroid hormone) for Injection, 75 mcg, 2 pack medication cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NPS Pharmaceuticals, Inc., Lexington, MA NDC 68875-0204-02

Lot numbers, UPCs & expiration codes

06628462, exp 5/31/2020 06651000, exp 9/30/2020 06661659, exp 6/30/2020 07110125, 07301073, exp 10/31/2020 07200435, 7/31/2020 07482211, exp 12/31/2020 07630714, exp 3/31/2021 NX170002DA, exp 12/31/2019 NX17004DA, exp 3/31/2020 NX17007DA, NX17007DB, NX17008DA exp 4/30/2020 NX17010DA, NX17012DA, exp 6/30/2020

Where it was sold

Product was distributed throughout the United States.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0037-2020
Classification
Class I
Status
Terminated
Recall initiated
Sep 12, 2019
FDA report date
Oct 2, 2019
Quantity
15,075
Recall type
Voluntary: Firm initiated
Recalling firm
Shire Human Genetic Therapies, Inc.

Original FDA data

Every field from FDA enforcement report D-0037-2020, exactly as published.

Show all FDA fields
City
Lexington
State
MA
Status
Terminated
Country
United States
Event ID
83792
Address
300 Shire Way
Code information
06628462, exp 5/31/2020 06651000, exp 9/30/2020 06661659, exp 6/30/2020 07110125, 07301073, exp 10/31/2020 07200435, 7/31/2020 07482211, exp 12/31/2020 07630714, exp 3/31/2021 NX170002DA, exp 12/31/2019 NX17004DA, exp 3/31/2020 NX17007DA, NX17007DB, NX17008DA exp 4/30/2020 NX17010DA, NX17012DA, exp 6/30/2020
Postal code
02421-2101
Report date
Oct 2, 2019
Product type
Drugs
Recall number
D-0037-2020
Classification
Class I
Recalling firm
Shire Human Genetic Therapies, Inc.
Product quantity
15,075
Termination date
Mar 23, 2021
Reason for recall
Defective Delivery System: potential risk of rubber stopper particles clogging the needle and leading to underdosing
Voluntary / mandated
Voluntary: Firm initiated
Product description
Natpara (parathyroid hormone) for Injection, 75 mcg, 2 pack medication cartridges, Rx only, For subcutaneous use only, Manufactured for: Shire-NPS Pharmaceuticals, Inc., Lexington, MA NDC 68875-0204-02
Distribution pattern
Product was distributed throughout the United States.
Recall initiation date
Sep 12, 2019
Initial firm notification
Letter
Center classification date
Oct 1, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0037-2020, published Oct 2, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls